Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
| 31.6 | |
| 31.6 | |
| - | |
| 31.6 | |
| 31.6 | |
| 19.9-38 | |
| 1 132 M | |
| 14.1126 | |
| 32 715 K | |
| 567 M | |
| 0.83 | |
| 0.926 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Collegium Pharmaceutical (COLL), which belongs to...
Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical Inc (NASDAQ:COLL), has sold 23,560 shares of the company on January 16, 2024, according to a recent SEC Filing. Collegium Pharm...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
